Mechanisms of Resistance to Endocrine Therapy in Breast Cancer: Focus on Signaling Pathways, miRNAs and Genetically Based Resistance
Open Access
- 19 December 2012
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 14 (1), 108-145
- https://doi.org/10.3390/ijms14010108
Abstract
Breast cancer is the most frequent malignancy diagnosed in women. Approximately 70% of breast tumors express the estrogen receptor (ER). Tamoxifen and aromatase inhibitors (AIs) are the most common and effective therapies for patients with ERα-positive breast cancer. Alone or combined with chemotherapy, tamoxifen significantly reduces disease progression and is associated with more favorable impact on survival in patients. Unfortunately, endocrine resistance occurs, either de novo or acquired during the course of the treatment. The mechanisms that contribute to hormonal resistance include loss or modification in the ERα expression, regulation of signal transduction pathways, altered expression of specific microRNAs, balance of co-regulatory proteins, and genetic polymorphisms involved in tamoxifen metabolic activity. Because of the clinical consequences of endocrine resistance, new treatment strategies are arising to make the cells sensitive to tamoxifen. Here, we will review the current knowledge on mechanisms of endocrine resistance in breast cancer cells. In addition, we will discuss novel therapeutic strategies to overcome such resistance. Undoubtedly, circumventing endocrine resistance should help to improve therapy for the benefit of breast cancer patients.This publication has 263 references indexed in Scilit:
- Differential expression of microRNA expression in tamoxifen-sensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cellsCancer Letters, 2011
- MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathwaysOncogene, 2010
- Conserved estrogen binding and signaling functions of the G protein-coupled estrogen receptor 1 (GPER) in mammals and fishSteroids, 2010
- Estrogen receptor alpha 46 is reduced in tamoxifen resistant breast cancer cells and re-expression inhibits cell proliferation and estrogen receptor alpha 66-regulated target gene transcriptionMolecular and Cellular Endocrinology, 2010
- Epigenetic Regulation in Estrogen Receptor Positive Breast Cancer—Role in Treatment ResponseJournal of Mammary Gland Biology and Neoplasia, 2010
- The role of microRNA-128a in regulating TGFbeta signaling in letrozole-resistant breast cancer cellsBreast Cancer Research and Treatment, 2010
- Biological determinants of endocrine resistance in breast cancerNature Reviews Cancer, 2009
- Regulation of ERBB2 by oestrogen receptor–PAX2 determines response to tamoxifenNature, 2008
- Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trialThe Lancet Oncology, 2008
- Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-ANature, 1986